Teladoc Q2 Earnings Beat Expectations with $631.9M Revenue

Teladoc reported Q2 EPS of 19 cents, beating consensus estimates of 31 cents. Revenue was $631.9 million, also exceeding the consensus estimate of $622.4 million. CEO Chuck Divita attributed the strong performance to disciplined execution and strategic priorities.

Teladoc Health, Inc. (TDOC) reported a quarterly loss of 19 cents per share, surpassing the Zacks Consensus Estimate of 27 cents. This compares to a loss of 28 cents per share a year ago, adjusted for non-recurring items [1]. The company also reported revenues of $631.9 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate of $620.91 million [3].

CEO Chuck Divita attributed the strong performance to disciplined execution and strategic priorities. The company has consistently beaten consensus EPS estimates over the last four quarters and has topped consensus revenue estimates four times in the same period [1].

The stock has lost about 9.8% since the beginning of the year, while the S&P 500 has gained 8.6% [1]. The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call.

Investors should keep an eye on the company's earnings outlook and the industry's outlook. The Medical Services industry is currently in the top 37% of the 250 plus Zacks industries [1]. Another stock from the same industry, Cencora (COR), is expected to report results on August 6 [1].

References:
[1] https://www.nasdaq.com/articles/teladoc-tdoc-reports-q2-loss-beats-revenue-estimates
[2] https://finance.yahoo.com/news/teladoc-tdoc-reports-q2-loss-220501306.html
[3] https://www.nasdaq.com/articles/teladoc-tdoc-q2-earnings-taking-look-key-metrics-versus-estimates